http://www.acc.org/Feed?clinicalTopicID=a91761fa-5431-434b-b7d3-9c8977ea5d76 Clinical Topic Feed: Homozygous Familial Hypercholesterolemia en /Latest-in-Cardiology/Articles/2026/07/21/12/01/FDA-Update The U.S. Food and Drug Administration (FDA) has approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor, to lower LDL cholesterol in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH). 1784635560000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/06/03/20/12/New-Research Three new studies published in Circulation highlight advances in lipid-lowering therapy, with early-stage data supporting a first-in-class oral PCSK9 inhibitor and two separate analyses showing that evolocumab reduces major cardiovascular events across a range of high-risk patients, including those with elevated Lp(a) and those with prior PCI but no history of MI. 1780519500000 Articles and Stories /Latest-in-Cardiology/Articles/2026/05/01/01/JACC-in-a-Flash Featured topics and Editors' Picks from all of ACC's JACC Journals. 1777637400000 Articles and Stories /Latest-in-Cardiology/Articles/2026/04/15/17/13/Sex-Specific-Differences-in-CVD-Risk-Factors-in-South-Korea In adults with cardiovascular disease in South Korea, the rates of awareness and treatment of key cardiovascular risk factors were higher in women than in men, but they had lower rates of risk factor control, particularly for hypertension and hypercholesterolemia... 1776367320000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/25/21/27/mon-1045am-coralreef-acc-2026 The novel PCSK9 oral inhibitor enlicitide effectively lowered LDL-C in adults already being treated with statins, demonstrating a potential role as an add-on option for patients not meeting LDL-C goals, according to results from the CORALreef AddOn trial presented during an Investigative Horizons session at ACC.26 in New Orleans and simultaneously published in JACC. 1774885560000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/03/24/18/20/ACC-Scientific-Statement-Highlights-Emerging-Role-of-Gene-Editing A new ACC Scientific Statement outlines the rapidly evolving landscape of gene-editing therapies and their growing relevance to cardiovascular disease, offering clinicians an overview of both the promise and the challenges of this transformative technology. 1774536660000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/01/20/18/24/Anti-ANGPTL3-Antibody SHR-1918, a fully human monoclonal antibody targeting angiopoietinlike 3 (ANGPTL3), was associated with a manageable safety profile and substantial reduction in LDL-C in patients with homozygous familiar hypercholesterolemia (HoFH) already taking stable lipid-lowering therapy... 1768998600000 Articles and Stories /Latest-in-Cardiology/Articles/2025/11/25/17/05/eagles-eye-view-03dec2025 In this week’s View, Dr. Eagle looks at the potential for electrophysiology (EP) ablation in ambulatory care. He then explores several new studies that reveal the rising rates of heart failure and hypertension. 1764769080000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2025/11/26/14/25/New-Studies-Reveal-Rising-Rates-of-HF-and-HBP The prevalence of heart failure (HF) and hypertension, respectively, are on the rise among U.S. adults, according to two separate studies published in JACC that use data from the National Health and Nutrition Examination Survey (NHANES). 1764170460000 Articles and Stories /Latest-in-Cardiology/Articles/2025/11/06/13/19/JACC-Journals-Publish-Latest-Science-From-aha-2025 AHA 2025 features key science simultaneously published across ACC's JACC Journals, including JACC, JACC: CardioOncology, JACC: Advances, JACC: Case Reports, JACC: Heart Failure and JACC: Cardiovascular Imaging. 1762527600000 Articles and Stories